Genmab — August 2017
-
God morgen.
-
-
God morgen
-
Short interview with head of the Myeloma Section at Moffitt Cancer Center http://www.onclive.com/web-exclusives/plethora-of-novel-agents-transforming-outcomes-in-multiple-myeloma
-
Panobinostat som cd38 booster nu afprøvet sammen med dara på patienter. På ASH var det kun præklinisk. "significant increase in ADCC" http://www.bloodjournal.org/content/129/25/3386
-
Punktform og lettere at læse her: http://www.multiplemyelomahub.com/medical-information/panobinostat-works-synergistically-with-daratumumab-by-up-regulating-cd38
-
Ferydak er godkendt i RRMM http://www.farydak.com/pivotal-trial/panorama-1/
-
Er det AB der sælger ud af arvesølvet?
-
royal, det var en netbankhandel i Lån & Spar. En kunde har f.eks. købt/solgt 100 stk. fordelt på 73 stk. i 1411 og 27 stk. i 1412
-
Bryan Garnier om Zeal: Of course, Soliqua remains a meaningful part of the story in the short term and represents a risk of volatility since the numbers are unlikely to be meaningful until the end of 2017. But dasiglucagon and glepaglutide are increasingly heavy in the FV, which we see as very positive for the investment case. In less than 12 months, the group will have two molecules in phase III trials.
-
ups, skulle have været i bava/zeal debatten
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind